Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases

Creative Commons License

ÖZTAY F. , Yılmaz Ö.

Diğer, ss.1-6, 2016

  • Basım Tarihi: 2016
  • Sayfa Sayıları: ss.1-6


The present invention relates to the use of dasatinib or its pharmaceutically acceptable salts thereof as a potential pharmaceutical agent, more preferably anti-proliferative or anti-fibrotic agent in fibrotic lung diseases, in particular idiopathic pulmoner fibrosis (IPF) disease.